Insider · CIK 0001750083
Tamar Elkeles
Files at PETS (PETMED EXPRESS INC), BTLN (Glimpse Group, Inc.). First filing -, latest -.
In brief
Tamar Elkeles files SEC Form 4 as director at PETS (PETMED EXPRESS INC), and also at BTLN (Glimpse Group, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Tamar Elkeles has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | PETS PETMED EXPRESS INC | AGrant or award Common Stock | +49,923 | $0.00 | $0 | 49,923 | 22 d ago |
| Jul 10, 2026 | BTLN Glimpse Group, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +174,368 | $0.00 | $0 | 174,368 | Aug 6, 2026 |
| Jan 1, 2025 | BTLN Glimpse Group, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 18, 2026 |
| May 1, 2026 | BTLN Glimpse Group, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Jun 18, 2026 |
Questions about Tamar Elkeles
Answered from the filings on this page, as of the latest one.
Is Tamar Elkeles buying or selling?
Tamar Elkeles has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Tamar Elkeles's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Tamar Elkeles has 0.
Where does Tamar Elkeles file Form 4?
Tamar Elkeles has filed Form 4 at PETS (PETMED EXPRESS INC); BTLN (Glimpse Group, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.